Patients with clinical signs and symptoms of active TB whose specimen is suitable for AFB microscopy and culture, and who have had < 3 days of anti-TB treatment
Subpopulations for analysis:
those with a high pre-test probability of active TB, e.g. come from a country with high rates of TB, versus those with a low pre-test probability of TB
Intervention
AFB microscopy plus NAAT for the detection of MTB-complex DNA ± culture
Randomised trials, cohort studies, case series or systematic reviews of these study designs
Search period
1990 – May 2014 or inception of the database if later than 1990
Language
Studies in languages other than English were excluded unless they represented a higher level of evidence than that available in the English language evidence-base
Seventeen studies reporting change in management outcomes due to NAAT were identified. Eight of these studies were conducted in developing countries with a high TB-prevalence (e.g. South-Africa, Uganda, Peru) and 8 studies were conducted in low-prevalence countries (e.g. USA, UK, Canada). The remaining study was conducted in a country with an intermediate TB burden (Korea). Only two studies used in-house NAATs and the remainder used commercial NAAT, of which 12 used the Xpert NAAT. The study profiles are summarised in Table (Appendix ) and an overall summary of the body of evidence is presented in Table .
Table Body of evidence matrix for studies reporting change in management outcomes due to NAAT